<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">Combination therapy may also be an option. A small study randomized hospitalized adults to rimantadine monotherapy or rimantadine-nebulized zanamivir combination therapy. The combination arm had a trend to less cough and fewer patients with detection of M2 inhibitor resistance mutations over the course of therapy [
 <xref ref-type="bibr" rid="CR54">54</xref>]. Recently, a triple combination of amantadine, oseltamivir, and ribavirin has been studied in vitro, in vivo, and in infected patient and appears effective at inhibiting viral replication in vitro and improved outcomes in vivo [
 <xref ref-type="bibr" rid="CR65">65</xref>, 
 <xref ref-type="bibr" rid="CR66">66</xref>].
</p>
